Detailansicht

Wissensnetz

Person

Joachim Peter Steinbach (1966-)

Name	Joachim Peter Steinbach
Zeit	1966- (Lebensdaten)
Ort	Tübingen (Geburtsort) Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Variante	Joachim P. Steinbach J. P. Steinbach
Beziehung	Universitätsklinikum Frankfurt
Weitere Angaben	Habil. Fachgebiet Allgemeine Neurologie der Medizinischen Fakultät der Univ. Tübingen (2005); Diss. Univ. Tübingen (1993)
Datensatztyp	Person
GND-Nummer	113564813
Datensatz-ID	113564813
Beteiligt an alle anzeigen Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas [P-06-05] A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression Modulation von Stammzellcharakteristika in Gliom-initiierenden Zellen durch GANT61 oder Arsentrioxid und (-)-Gossypol High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management Bedeutung von SAMHD1 als Resistenzfaktor im humanen Neuroblastom Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment Immune checkpoint inhibitor-induced cerebral pseudoprogression: patterns and categorization Molecular matched targeted therapies for primary brain tumors - a single center retrospective analysis Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter Pulmonary resection after radiosurgery and neoadjuvant immunochemotherapy for NSCLC patients with synchronous brain metastasis — a case series of three patients The acute superficial siderosis syndrome — clinical entity, imaging findings, and histopathology Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial Single-shot bevacizumab for cerebral radiation injury A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy A paravermal rtans-cerebellar approach to the posterior fossa tumor causes hypertrophic olivary degeneration by dentate nucleus injury Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy Matching quantitative MRI parameters with histological features of treatment-naïve IDH wild-type glioma Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial Single-shot bevacizumab for cerebral radiation injury Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes Activation of epidermal growth factor receptor sensitizes glioblastoma cells to hypoxia-induced cell death Cetuximab-mediated protection from hypoxia-induced cell death: implications for therapy sequence in colorectal cancer Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma Maintenance of energy homeostasis during calorically restricted ketogenic diet and fasting-MR-spectroscopic insights from the ERGO2 trial Non-invasive measurement of drug and 2-HG signals using 19F and 1H MR spectroscopy in brain tumors treated with the mutant IDH1 inhibitor BAY1436032 Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab Car-engineered nk cells for the treatment of glioblastoma: Turning innate effectors into precision tools for cancer immunotherapy Delayed occurrence of hypertrophic olivary degeneration after therapy of posterior fossa tumors: A single institution retrospective analysis Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients Second generation mtor inhibitors as a double-edged sword in malignant glioma treatment The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern Bevacizumab for patients with recurrent multifocal glioblastomas Biomarker and histopathology evaluation of patients with recurrent glioblastoma treated with galunisertib, lomustine, or the combination of galunisertib and lomustine Myoinositol as a biomarker in recurrent glioblastoma treated with bevacizumab : a 1H-magnetic resonance spectroscopy study Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors Hypoxia enhances the antiglioma cytotoxicity of b10, a glycosylated derivative of betulinic acid Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases Phospholipid metabolites in recurrent glioblastoma : in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy Signaltransduktion bei malignen Gliomzellen : paradoxe Bedeutung für Todesliganden-induzierte Apoptose und hypoxischen Zelltod Immunologische Charakterisierung von Fibroblasten

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Joachim Peter Steinbach (1966-)

Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas

[P-06-05] A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression

Modulation von Stammzellcharakteristika in Gliom-initiierenden Zellen durch GANT61 oder Arsentrioxid und (-)-Gossypol

High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors

Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management

Bedeutung von SAMHD1 als Resistenzfaktor im humanen Neuroblastom

Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management

DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis

DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment

Immune checkpoint inhibitor-induced cerebral pseudoprogression: patterns and categorization

Molecular matched targeted therapies for primary brain tumors - a single center retrospective analysis

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Pulmonary resection after radiosurgery and neoadjuvant immunochemotherapy for NSCLC patients with synchronous brain metastasis — a case series of three patients

The acute superficial siderosis syndrome — clinical entity, imaging findings, and histopathology

Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial

Single-shot bevacizumab for cerebral radiation injury

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy

A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy

A paravermal rtans-cerebellar approach to the posterior fossa tumor causes hypertrophic olivary degeneration by dentate nucleus injury

Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide

Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy

Matching quantitative MRI parameters with histological features of treatment-naïve IDH wild-type glioma

Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial

Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial

Single-shot bevacizumab for cerebral radiation injury

Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis

Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes

Activation of epidermal growth factor receptor sensitizes glioblastoma cells to hypoxia-induced cell death

Cetuximab-mediated protection from hypoxia-induced cell death: implications for therapy sequence in colorectal cancer

Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma

Maintenance of energy homeostasis during calorically restricted ketogenic diet and fasting-MR-spectroscopic insights from the ERGO2 trial

Non-invasive measurement of drug and 2-HG signals using 19F and 1H MR spectroscopy in brain tumors treated with the mutant IDH1 inhibitor BAY1436032

Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes

Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes

The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma

Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab

Car-engineered nk cells for the treatment of glioblastoma: Turning innate effectors into precision tools for cancer immunotherapy

Delayed occurrence of hypertrophic olivary degeneration after therapy of posterior fossa tumors: A single institution retrospective analysis

Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas

Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients

Second generation mtor inhibitors as a double-edged sword in malignant glioma treatment

The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma

ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors

Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern

Bevacizumab for patients with recurrent multifocal glioblastomas

Biomarker and histopathology evaluation of patients with recurrent glioblastoma treated with galunisertib, lomustine, or the combination of galunisertib and lomustine

Myoinositol as a biomarker in recurrent glioblastoma treated with bevacizumab : a 1H-magnetic resonance spectroscopy study

Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors

Hypoxia enhances the antiglioma cytotoxicity of b10, a glycosylated derivative of betulinic acid

Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases

Phospholipid metabolites in recurrent glioblastoma : in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy

Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy

Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy

Signaltransduktion bei malignen Gliomzellen : paradoxe Bedeutung für Todesliganden-induzierte Apoptose und hypoxischen Zelltod

Immunologische Charakterisierung von Fibroblasten